SG10202100598RA - Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity - Google Patents
Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding CapacityInfo
- Publication number
- SG10202100598RA SG10202100598RA SG10202100598RA SG10202100598RA SG10202100598RA SG 10202100598R A SG10202100598R A SG 10202100598RA SG 10202100598R A SG10202100598R A SG 10202100598RA SG 10202100598R A SG10202100598R A SG 10202100598RA SG 10202100598R A SG10202100598R A SG 10202100598RA
- Authority
- SG
- Singapore
- Prior art keywords
- evs
- detection
- protein
- polypeptide
- containing protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1612643.5A GB2552473A (en) | 2016-07-21 | 2016-07-21 | Surface decoration of extracellular vesicles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202100598RA true SG10202100598RA (en) | 2021-02-25 |
Family
ID=56894359
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100598RA SG10202100598RA (en) | 2016-07-21 | 2017-07-21 | Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity |
| SG11201811152YA SG11201811152YA (en) | 2016-07-21 | 2017-07-21 | Uses of extracellular vesicle comprising a fusion protein having fc binding capacity |
| SG10202100597TA SG10202100597TA (en) | 2016-07-21 | 2017-07-21 | Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity |
| SG11201811151PA SG11201811151PA (en) | 2016-07-21 | 2017-07-21 | Extracellular vesicle comprising a fusion protein having fc binding capacity |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811152YA SG11201811152YA (en) | 2016-07-21 | 2017-07-21 | Uses of extracellular vesicle comprising a fusion protein having fc binding capacity |
| SG10202100597TA SG10202100597TA (en) | 2016-07-21 | 2017-07-21 | Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity |
| SG11201811151PA SG11201811151PA (en) | 2016-07-21 | 2017-07-21 | Extracellular vesicle comprising a fusion protein having fc binding capacity |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11236143B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4299137A3 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7140743B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102636776B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109689097B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017299214A1 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112019001108A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3031183A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2552473A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019000863A (cg-RX-API-DMAC7.html) |
| SG (4) | SG10202100598RA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2018015535A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012040623A2 (en) | 2010-09-24 | 2012-03-29 | The Brigham And Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
| GB2552774A (en) * | 2016-07-12 | 2018-02-14 | Evox Therapeutics Ltd | EV-Mediated delivery of binding protein-small molecule conjugates |
| GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
| WO2018144991A1 (en) | 2017-02-03 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
| GB201702863D0 (en) * | 2017-02-22 | 2017-04-05 | Evox Therapeutics Ltd | Improved loading of EVs with therapeutic proteins |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| GB201717446D0 (en) | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| GB201804291D0 (en) * | 2018-03-16 | 2018-05-02 | Evox Therapeutics Ltd | Cell-mediated exosome delivery |
| US20190307885A1 (en) | 2018-04-04 | 2019-10-10 | Alivio Therapeutics, Inc. | Self-assembled gels for controlled delivery of biologics and methods of making thereof |
| TWI770396B (zh) * | 2018-06-28 | 2022-07-11 | 中央研究院 | 合成多肽及其用途 |
| KR102917499B1 (ko) | 2018-07-20 | 2026-01-26 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법 |
| GB201812992D0 (en) | 2018-08-09 | 2018-09-26 | Univ Greenwich | Liposomes |
| BR112021002710A2 (pt) | 2018-08-14 | 2021-11-16 | Evercyte Gmbh | Vesículas extracelulares específicas alvo (tev), uma preparação, uma proteína de superfície da vesícula extracelular específica alvo, um domínio extravesicular específico alvo da mesma. codificação de ácido nucleico, biblioteca de tev, preparação farmacêutica e sua utilização; métodos de produção |
| CN108998402B (zh) * | 2018-08-28 | 2020-05-29 | 江南大学 | 一种重组枯草芽孢杆菌及其构建方法与应用 |
| US20210317479A1 (en) | 2018-09-06 | 2021-10-14 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
| SG11202103756XA (en) * | 2018-10-19 | 2021-05-28 | Ohio State Innovation Foundation | Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells |
| CN113166267A (zh) | 2018-10-19 | 2021-07-23 | 俄亥俄州国家创新基金会 | 纳米工程化治疗性隐形细胞 |
| JP7577335B2 (ja) | 2018-10-19 | 2024-11-05 | オハイオ・ステイト・イノベーション・ファウンデーション | 肺炎症治療用のナノキャリア |
| CN113301914B (zh) * | 2018-10-25 | 2026-02-03 | 尼希尔有限公司 | 用于治疗和预防纤维化的组合物和方法 |
| CN113272426A (zh) * | 2018-11-16 | 2021-08-17 | 医福斯治疗有限公司 | 用于尿素循环蛋白和核酸的替代的细胞外囊泡 |
| SG11202107007VA (en) * | 2018-12-27 | 2021-07-29 | Akeso Biopharma Inc | Antibody against human il-4ra and use thereof |
| JP2022519275A (ja) * | 2019-02-04 | 2022-03-22 | コディアック バイオサイエンシーズ, インコーポレイテッド | エクソソーム操作のための膜タンパク質足場 |
| US12357704B2 (en) | 2019-05-06 | 2025-07-15 | Thomas Malcolm | Tailored hypoimmune nanovesicular delivery systems for cancer tumors |
| US20220259617A1 (en) * | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| WO2020249757A1 (en) * | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| AU2020298314A1 (en) * | 2019-06-21 | 2022-02-03 | Entelexo Biotherapeutics Inc. | Platforms, compositions, and methods for therapeutics delivery |
| JP7898376B2 (ja) * | 2019-08-06 | 2026-07-31 | オハイオ・ステイト・イノベーション・ファウンデーション | 治療用細胞外小胞 |
| EP3973969A4 (en) * | 2019-09-02 | 2023-07-12 | Kyungpook National University Industry-Academic Cooperation Foundation | COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IL-2 EXTRACELLULAR SURFACE EXPRESSION VESICLES AS AN ACTIVE AGENT |
| CN115942957A (zh) * | 2019-11-04 | 2023-04-07 | 阿鲁纳生物股份公司 | 细胞外囊泡及其用于抗体递送的用途 |
| CN112941028A (zh) * | 2019-12-09 | 2021-06-11 | 上海细胞治疗集团有限公司 | 纳米抗体基因修饰的间充质干细胞及其制备方法与应用 |
| KR20220139926A (ko) | 2020-02-05 | 2022-10-17 | 다이아뎀 바이오쎄라퓨틱스 인크 | 인공 시냅스 |
| WO2021211460A1 (en) * | 2020-04-13 | 2021-10-21 | City Of Hope | Cell-receptor targeted exosomes |
| CN111544453B (zh) * | 2020-04-27 | 2021-01-22 | 高连如 | 一种包含三种血管再生属性的混合干细胞注射液及其制备方法 |
| CN111560352B (zh) * | 2020-06-02 | 2023-03-24 | 新疆农业大学 | 一种病毒样囊泡及其制备方法和应用 |
| CN111905105B (zh) * | 2020-07-02 | 2023-05-05 | 华南师范大学 | 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法 |
| CN112111513A (zh) * | 2020-07-17 | 2020-12-22 | 深圳市第二人民医院 | 基于外泌体平台的新冠病毒疫苗制备方法 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| CN113967254B (zh) * | 2020-08-04 | 2022-08-12 | 华南理工大学 | 用于多特异性抗体递送的细胞膜包覆型纳米适配子及应用 |
| JP2023536665A (ja) * | 2020-08-05 | 2023-08-28 | オハイオ・ステイト・イノベーション・ファウンデーション | アダプターポリペプチドおよびその使用方法 |
| CN112285195B (zh) * | 2020-10-27 | 2021-08-10 | 江南大学 | 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法 |
| WO2022149779A1 (ko) * | 2021-01-11 | 2022-07-14 | 주식회사 엑소코바이오 | 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법 |
| KR102252325B1 (ko) * | 2021-01-14 | 2021-05-14 | 이장호 | 태아 유래 태초 면역글로불린을 포함하는 세포외소포의 제조방법 |
| WO2022158836A1 (ko) * | 2021-01-21 | 2022-07-28 | 주식회사 엑소코바이오 | 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도 |
| WO2022219075A2 (en) * | 2021-04-14 | 2022-10-20 | Anjarium Biosciences Ag | Peptides, nanovesicles, and uses thereof for drug delivery |
| EP4323396A1 (en) * | 2021-04-14 | 2024-02-21 | Anjarium Biosciences AG | Fc-derived polypeptides |
| JP2024518732A (ja) * | 2021-04-23 | 2024-05-02 | スポット バイオシステムズ リミテッド | 生体分子がロードされた細胞外小胞 |
| GB202107182D0 (en) * | 2021-05-19 | 2021-06-30 | Evox Therapeutics Ltd | Nanoparticle delivery system for production of engineered extracellular vesicles |
| EP4355304A4 (en) * | 2021-06-17 | 2025-04-30 | Malcolm, Thomas | PERSONALIZED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCERS, INHERITED DISEASES AND INFECTIOUS DISEASES |
| CN115770302A (zh) * | 2021-08-13 | 2023-03-10 | 南京大学 | 一种rna递送系统及其应用 |
| CN113599516B (zh) * | 2021-08-16 | 2022-02-18 | 上海蒙彼利生物技术有限公司 | 制备外泌体方法及其药物组合物在组织修复中的应用 |
| KR102577502B1 (ko) * | 2021-09-08 | 2023-09-13 | 주식회사 꿈랩 | 생체분자의 안정적 발현 및 전달을 위한 플라스미드 플랫폼 |
| CN113897387B (zh) * | 2021-10-09 | 2023-09-05 | 深圳市汉科生命工程有限公司 | 一种具有促进毛发再生功能的基因重组msc及其外泌体样纳米材料的制备方法和应用 |
| WO2023076768A1 (en) * | 2021-10-26 | 2023-05-04 | Navicure Biopharmaceuticals Limited | Combination therapies against cancer and infectious diseases |
| CN116218780A (zh) * | 2021-12-03 | 2023-06-06 | 洪明奇 | 外泌体的生产及其用途 |
| CN114107253B (zh) * | 2021-12-17 | 2024-03-15 | 复旦大学附属华山医院 | 一种利用工程细胞进行基因编辑的系统及方法 |
| CN114236113B (zh) * | 2021-12-21 | 2023-07-21 | 南京农业大学 | 一种2,4-滴的即用型免疫传感器 |
| WO2023133425A1 (en) * | 2022-01-04 | 2023-07-13 | The Broad Institute, Inc. | Compositions and methods for delivering cargo to a target cell |
| WO2023196586A1 (en) * | 2022-04-07 | 2023-10-12 | The Regents Of The University Of Michigan | Methods and devices for screening extracellular vesicles |
| CN116903712A (zh) * | 2022-04-12 | 2023-10-20 | 四川大学华西医院 | 一种人源IgG结合肽及其用途 |
| WO2024064748A2 (en) * | 2022-09-20 | 2024-03-28 | North Carolina State University | Compositions and methods related to exosomal delivery of therapeutic agents |
| CN116179582A (zh) * | 2022-09-27 | 2023-05-30 | 南京医事达生物科技有限公司 | 一种通用型基因重组蛋白质a亲和纯化填料制备方法和应用 |
| CN117802045A (zh) * | 2022-09-30 | 2024-04-02 | 北京恩康医药有限公司 | 一种工程化细胞外囊泡的构建及其应用 |
| CN115873905A (zh) * | 2022-11-15 | 2023-03-31 | 重庆医科大学附属儿童医院 | 一种gd2纳米抗体靶向修饰的类外泌体的新型药物载体的制备方法 |
| KR102929157B1 (ko) | 2023-03-08 | 2026-02-23 | 차이나 메디칼 유니버시티 | 엑소좀의 생산 및 이의 용도 |
| KR20240158824A (ko) * | 2023-04-26 | 2024-11-05 | (주)인엑소플랫 | 면역글로불린 Fc 영역 또는 이의 변이체를 포함하는 재조합 세포외 소포체 및 이를 이용한 세포외 소포체의 분리 방법 |
| KR20240159543A (ko) * | 2023-04-28 | 2024-11-05 | 연세대학교 산학협력단 | 유방암 유래 엑소좀 또는 세포외 소포체 분리 방법 |
| GB202307239D0 (en) | 2023-05-15 | 2023-06-28 | Evox Therapeutics Ltd | Gene therapies for Phenylketonuria |
| CN119120376A (zh) * | 2023-07-10 | 2024-12-13 | 浙江大学医学院附属第一医院 | 一种用于清除致病抗体的嵌合基因工程化纳米囊泡及其制备方法、应用 |
| EP4784736A2 (en) | 2023-09-29 | 2026-08-05 | Evox Therapeutics Limited | Polypeptides comprising inteins for engineered evs |
| WO2025102257A1 (zh) * | 2023-11-15 | 2025-05-22 | 深圳先进技术研究院 | 一种靶向子宫工程化细胞外囊泡的制备方法及其应用 |
| WO2025217863A1 (zh) * | 2024-04-18 | 2025-10-23 | 苏州鲲石一号生物科技有限公司 | Gas6融合蛋白及其制备方法与应用 |
| CN118725135B (zh) * | 2024-09-02 | 2025-02-07 | 中国科学院苏州纳米技术与纳米仿生研究所 | 外泌体的改造方法 |
| CN119019494B (zh) * | 2024-10-28 | 2025-02-07 | 广州飞来爱生命科技有限公司 | 一种治疗心梗的脐带间充质干细胞及其制备方法和应用 |
| GB2702728A (en) | 2024-10-29 | 2026-06-24 | Evox Therapeutics Ltd | Crispr rna molecules for improved ev-mediated delivery of cas12 rnp complexes |
| AU2026200047A1 (en) * | 2025-01-10 | 2026-07-30 | China Medical University | Central nervous system targeting pharmaceutical composition |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4090299A (en) * | 1998-05-20 | 1999-12-06 | Sdg, Inc. | Liposomal delivery complex |
| US20040241176A1 (en) * | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
| US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
| JP2007295929A (ja) * | 2006-04-05 | 2007-11-15 | Geno Membrane:Kk | イヌBsep遺伝子 |
| EP2198033A4 (en) * | 2007-08-30 | 2011-05-25 | Virexx Medical Corp | ANTIGENIC COMPOSITIONS AND USE THEREOF IN THE TARGETED INTRODUCTION OF NUCLEIC ACIDS |
| AU2008303057B2 (en) * | 2007-09-24 | 2014-09-04 | The University Of Queensland | Molecular delivery vesicle |
| PT2419144T (pt) * | 2009-04-17 | 2019-09-16 | Univ Oxford Innovation Ltd | Composição para a administração de material genético |
| SG191233A1 (en) * | 2010-12-23 | 2013-07-31 | Janssen Biotech Inc | Active protease-resistant antibody fc mutants |
| DK2675474T3 (en) * | 2011-02-15 | 2019-04-23 | Vaxiion Therapeutics Llc | THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES |
| GB201121069D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
| GB201121070D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| EP2983721B2 (en) * | 2013-04-12 | 2021-01-20 | Evox Therapeutics Limited | Therapeutic delivery vesicles |
| WO2015002956A1 (en) | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
| US10538570B2 (en) * | 2013-09-30 | 2020-01-21 | Northwestern University | Targeted and modular exosome loading system |
| WO2015058148A1 (en) * | 2013-10-17 | 2015-04-23 | Children's Hospital Los Angeles | Antibody dependent exosome therapy |
| WO2015143113A1 (en) * | 2014-03-20 | 2015-09-24 | Barb Ariel Cohen | Preparations of derived extracellular vesicles, assays, and methods to modify therapeutic outcomes using such preparations |
| GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
-
2016
- 2016-07-21 GB GB1612643.5A patent/GB2552473A/en not_active Withdrawn
-
2017
- 2017-07-21 SG SG10202100598RA patent/SG10202100598RA/en unknown
- 2017-07-21 SG SG11201811152YA patent/SG11201811152YA/en unknown
- 2017-07-21 WO PCT/EP2017/068476 patent/WO2018015535A1/en not_active Ceased
- 2017-07-21 MX MX2019000863A patent/MX2019000863A/es unknown
- 2017-07-21 AU AU2017299214A patent/AU2017299214A1/en not_active Abandoned
- 2017-07-21 BR BR112019001108A patent/BR112019001108A2/pt not_active IP Right Cessation
- 2017-07-21 EP EP23192812.8A patent/EP4299137A3/en not_active Withdrawn
- 2017-07-21 CN CN201780045139.XA patent/CN109689097B/zh not_active Expired - Fee Related
- 2017-07-21 US US16/319,061 patent/US11236143B2/en not_active Expired - Fee Related
- 2017-07-21 SG SG10202100597TA patent/SG10202100597TA/en unknown
- 2017-07-21 CA CA3031183A patent/CA3031183A1/en active Pending
- 2017-07-21 US US16/319,087 patent/US20230181757A1/en not_active Abandoned
- 2017-07-21 CN CN201780045183.0A patent/CN109689098A/zh active Pending
- 2017-07-21 EP EP17749397.0A patent/EP3487529A1/en not_active Withdrawn
- 2017-07-21 JP JP2019502253A patent/JP7140743B2/ja not_active Expired - Fee Related
- 2017-07-21 JP JP2019502697A patent/JP7254016B2/ja active Active
- 2017-07-21 EP EP17749395.4A patent/EP3487528B1/en active Active
- 2017-07-21 KR KR1020197005096A patent/KR102636776B1/ko active Active
- 2017-07-21 CA CA3031186A patent/CA3031186A1/en active Pending
- 2017-07-21 SG SG11201811151PA patent/SG11201811151PA/en unknown
- 2017-07-21 KR KR1020197005093A patent/KR20190032479A/ko not_active Withdrawn
- 2017-07-21 MX MX2019000861A patent/MX2019000861A/es unknown
- 2017-07-21 BR BR112019001099A patent/BR112019001099A2/pt not_active IP Right Cessation
- 2017-07-21 WO PCT/EP2017/068486 patent/WO2018015539A1/en not_active Ceased
- 2017-07-21 AU AU2017300035A patent/AU2017300035A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/551,582 patent/US20220098267A1/en not_active Abandoned
-
2022
- 2022-05-24 JP JP2022084613A patent/JP2022117998A/ja active Pending
- 2022-12-01 JP JP2022192884A patent/JP2023026440A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202100597TA (en) | Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity | |
| IL275426A (en) | Transgenic FC fusion proteins containing IL-2 | |
| SI3583125T1 (sl) | Fuzijski proteini z albumin-vezavno domeno | |
| IL254965A0 (en) | fusion proteins | |
| ZA201701810B (en) | Sirp-alpha immunoglobulin fusion proteins | |
| EP3502143A4 (en) | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN | |
| EP3233920A4 (en) | Single chain fc fusion proteins | |
| GB201509413D0 (en) | Fusion protein | |
| EP3148573A4 (en) | Ox40l fusion proteins and uses thereof | |
| GB201504691D0 (en) | Fusion protein | |
| ZA202003845B (en) | Fusion proteins | |
| EP2969009A4 (en) | MODIFIED FC FUSION PROTEINS | |
| ZA201606327B (en) | Uti fusion proteins | |
| ZA201801394B (en) | Fusion protein | |
| EP3099320A4 (en) | Protein m related immunoglobulin-binding polypeptides | |
| GB201712792D0 (en) | Fusion protein | |
| HK40008240A (en) | Uses of extracellular vesicle comprising a fusion protein having fc binding capacity | |
| GB201602850D0 (en) | Fusion proteins | |
| HK40008241A (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| HK40027661A (en) | Protein engineered extracellular vesicles | |
| HK1242337A1 (zh) | 單鏈fc 融合蛋白 |